A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations

  • Cancer
  • Lung Cancer
  • Non Small Cell Lung Carcinoma